David R. McAvoy - 05 Sep 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, Chief Legal Officer
Issuer ticker: TEVA
Reported as of: 05 Sep 2025
Net transaction value: +$20,988
SEC form: 4
Accepted by SEC: 09 Sep 2025, 16:02:56 UTC
Prior SEC filing: 07 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for David R. McAvoy

Key filing fact

David R. McAvoy filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 09 Sep 2025.

Key facts

This page summarizes David R. McAvoy's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Sep 2025, 16:02.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001758842 Primary reporting owner

Relationship: EVP, Chief Legal Officer
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for David R. McAvoy
Signature date: 09 Sep 2025

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Purchase

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.